Just earlier this week, we reported that a new study showed promise for ovarian cancer screening. A combo of transvaginal ultrasound and a CA125 blood test found early, treatable cancers, according to the research published in The Lancet Oncology. Study authors admitted that they weren't sure how the findings would translate into mortality or balance against the risks of screening.
Now it looks pretty clear that the results aren't going to be good, according to a second study. The new research, published in Obstetrics & Gynecology, found that the predictive value of the tests was only 1 to 1.3% and that a high percentage of the cancers found were late-stage. Scientists need to keep looking for a more sensitive and specific test, the study author told HealthDay.
Not a good week for screening tests.